Make a gift before the end of the year to drive research breakthroughs in 2026.
NETRF Annual Report 2019 looks at scientific milestones and educational innovations. It includes stories about some of the people who have supported us to fund more research projects than ever before and offer new ways to learn about NETs.
Results find delays in care and treatment, fear of exposure to COVID-19 The Neuroendocrine Tumor Research Foundation (NETRF) recently surveyed NET patients and caregivers about
Recognizing the mental and emotional stresses of living with cancer during COVID-19 and limiting the impact on your thoughts, behavior, and mood.
Tom Bajoras, a West Coast musician is taking advantage of gaps in his schedule to compose music to support his and your journey with NETs.
A new phase III clinical trial called COMPETE (NCT03049189 ) compares everolimus, an oral targeted therapy, to PRRT with Lu-177 edotreotide, a radiopharmaceutical under development,
Following the loss of a loved one, holiday traditions may be more painful than joyful. Many things can trigger memories that seem to amplify your
Approximately 20% of all primary lung tumors are neuroendocrine (Hung 2019), including: Typical carcinoid (TC) Atypical carcinoid (AC) Small cell carcinoma (SCC) Large cell carcinoma
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between the Gallium-68 PET/CT scan and prior technology. But are these newer imaging techniques better? And who stands to benefit most from them?
Many patients and families facing a neuroendocrine tumor (NET) diagnosis wonder if they inherited the disease from their parents or if they can pass it